Symbols / MIST $1.15 +14.10% Milestone Pharmaceuticals Inc.

Healthcare • Biotechnology • Canada • NMS
MIST Chart
About

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 135.60M
Enterprise Value -31.01M Income -63.06M Sales 1.55M
Book/sh 0.34 Cash/sh 6.46 Dividend Yield —
Payout 0.00% Employees 38 IPO —
P/E — Forward P/E -1.17 PEG —
P/S 87.71 P/B 3.38 P/C —
EV/EBITDA 0.50 EV/Sales -20.06 Quick Ratio 7.83
Current Ratio 8.01 Debt/Eq 139.76 LT Debt/Eq —
EPS (ttm) -0.75 EPS next Y -0.98 EPS Growth —
Revenue Growth — Earnings 2026-05-14 ROA -41.09%
ROE -229.65% ROIC — Gross Margin 100.00%
Oper. Margin -11.16% Profit Margin 0.00% Shs Outstand 117.67M
Shs Float 14.06M Short Float 10.28% Short Ratio 6.39
Short Interest — 52W High 3.06 52W Low 0.62
Beta 0.54 Avg Volume 2.27M Volume 1.38M
Target Price $6.60 Recom Buy Prev Close $1.01
Price $1.15 Change 14.10%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.60
Mean price target
2. Current target
$1.15
Latest analyst target
3. DCF / Fair value
$-4.42
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.15
Low
$2.00
High
$8.00
Mean
$6.60

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-06 reit HC Wainwright & Co. Buy → Buy $8
2025-12-16 main Wells Fargo Overweight → Overweight $8
2025-12-15 up TD Cowen Hold → Buy $8
2025-12-15 main HC Wainwright & Co. Buy → Buy $8
2025-09-11 init Wells Fargo — → Overweight $4
2025-04-01 main HC Wainwright & Co. Buy → Buy $10
2025-03-28 reit HC Wainwright & Co. Buy → Buy $25
2025-03-17 reit HC Wainwright & Co. Buy → Buy $25
2025-02-28 reit HC Wainwright & Co. Buy → Buy $25
2025-01-27 reit HC Wainwright & Co. Buy → Buy $25
2024-10-14 reit HC Wainwright & Co. Buy → Buy $25
2024-08-22 reit HC Wainwright & Co. Buy → Buy $25
2024-08-22 init Rodman & Renshaw — → Buy $9
2024-07-01 reit HC Wainwright & Co. Buy → Buy $25
2024-05-30 reit HC Wainwright & Co. Buy → Buy $25
2024-05-16 reit HC Wainwright & Co. Buy → Buy $25
2024-03-22 reit HC Wainwright & Co. Buy → Buy $25
2024-03-05 main Piper Sandler Overweight → Overweight $5
2024-02-26 reit HC Wainwright & Co. Buy → Buy $25
2023-12-27 main TD Cowen Outperform → Outperform $9
News
RSS: Latest MIST news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-26 OLIVETO JOSEPH GERARD Chief Executive Officer — 167,577 $1.93 $375,315
2026-01-26 MULLER LORENZ ANDREW Officer — 64,746 $1.93 $145,851
2026-01-26 HASIJA AMIT Chief Financial Officer — 70,252 $1.93 $158,209
2026-01-26 BHARUCHA DAVID Officer — 70,252 $1.93 $158,209
2026-01-26 NELSON JEFFREY EDWARD Chief Operating Officer — 70,252 $1.93 $158,209
2026-01-26 OLIVETO JOSEPH GERARD Chief Executive Officer — 66,600 — —
2026-01-26 MULLER LORENZ ANDREW Officer — 20,100 — —
2026-01-26 HASIJA AMIT Chief Financial Officer — 20,100 — —
2026-01-26 BHARUCHA DAVID Officer — 20,100 — —
2026-01-26 NELSON JEFFREY EDWARD Chief Operating Officer — 20,100 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1.55
0.00
-100.00%
1.00
-80.00%
5.00
Operating Revenue
1.55
0.00
-100.00%
1.00
-80.00%
5.00
Operating Expense
63.69
+51.27%
42.10
-32.20%
62.10
-3.94%
64.64
Research And Development
18.11
+26.13%
14.36
-53.76%
31.05
-22.04%
39.83
Selling General And Administration
45.58
+64.27%
27.75
-10.63%
31.05
+25.12%
24.81
Selling And Marketing Expense
28.30
+157.24%
11.00
-27.20%
15.11
+66.18%
9.10
General And Administrative Expense
17.27
+3.18%
16.74
+5.08%
15.93
+1.36%
15.72
Other Gand A
17.27
+3.18%
16.74
+5.08%
15.93
+1.36%
15.72
Total Expenses
63.69
+51.27%
42.10
-32.20%
62.10
-3.94%
64.64
Operating Income
-62.14
-47.59%
-42.10
+31.09%
-61.10
-2.44%
-59.64
Total Operating Income As Reported
-62.14
-47.59%
-42.10
+31.09%
-61.10
-2.44%
-59.64
EBITDA
-59.11
-56.23%
-37.83
+33.67%
-57.04
+2.16%
-58.30
Normalized EBITDA
-59.11
-56.23%
-37.83
+33.67%
-57.04
+2.16%
-58.30
Reconciled Depreciation
0.11
+8.57%
0.10
+14.13%
0.09
+3.37%
0.09
EBIT
-59.22
-56.10%
-37.94
+33.59%
-57.13
+2.15%
-58.39
Net Income
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Pretax Income
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Net Non Operating Interest Income Expense
-0.92
-257.46%
0.58
-58.74%
1.41
+12.68%
1.25
Interest Expense Non Operating
3.84
+7.18%
3.58
+40.21%
2.55
0.00
Net Interest Income
-0.92
-257.46%
0.58
-58.74%
1.41
+12.68%
1.25
Interest Expense
3.84
+7.18%
3.58
+40.21%
2.55
0.00
Interest Income Non Operating
2.92
-29.88%
4.16
+4.97%
3.97
+216.35%
1.25
Interest Income
2.92
-29.88%
4.16
+4.97%
3.97
+216.35%
1.25
Tax Provision
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Net Income From Continuing Operation Net Minority Interest
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Net Income From Continuing And Discontinued Operation
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Net Income Continuous Operations
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Normalized Income
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Net Income Common Stockholders
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Diluted EPS
—
-0.67
+51.80%
-1.39
-0.72%
-1.38
Basic EPS
—
-0.67
+51.80%
-1.39
-0.72%
-1.38
Basic Average Shares
—
62.21
+44.82%
42.96
+1.19%
42.45
Diluted Average Shares
—
62.21
+44.82%
42.96
+1.19%
42.45
Diluted NI Availto Com Stockholders
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Line Item Trend 2023-12-31
Total Assets
75.23
Current Assets
73.03
Cash Cash Equivalents And Short Term Investments
66.00
Cash And Cash Equivalents
13.76
Other Short Term Investments
52.24
Receivables
3.85
Other Receivables
2.42
Taxes Receivable
0.91
Accrued Interest Receivable
0.53
Inventory
—
Prepaid Assets
3.18
Total Non Current Assets
2.19
Net PPE
2.19
Gross PPE
2.38
Accumulated Depreciation
-0.19
Properties
0.00
Machinery Furniture Equipment
0.38
Other Properties
1.92
Leases
0.09
Total Liabilities Net Minority Interest
58.45
Current Liabilities
7.23
Payables And Accrued Expenses
5.97
Payables
3.98
Accounts Payable
3.98
Other Payable
—
Current Accrued Expenses
1.99
Pensionand Other Post Retirement Benefit Plans Current
0.71
Current Debt And Capital Lease Obligation
0.55
Current Capital Lease Obligation
0.55
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
51.23
Long Term Debt And Capital Lease Obligation
51.23
Long Term Debt
49.77
Long Term Capital Lease Obligation
1.46
Other Non Current Liabilities
—
Stockholders Equity
16.77
Common Stock Equity
16.77
Capital Stock
260.50
Common Stock
260.50
Share Issued
33.48
Ordinary Shares Number
33.48
Treasury Shares Number
0.00
Additional Paid In Capital
33.83
Retained Earnings
-326.03
Gains Losses Not Affecting Retained Earnings
—
Total Equity Gross Minority Interest
16.77
Total Capitalization
66.54
Working Capital
65.81
Invested Capital
66.54
Total Debt
51.77
Net Debt
36.01
Capital Lease Obligations
2.00
Net Tangible Assets
16.77
Tangible Book Value
16.77
Foreign Currency Translation Adjustments
—
Other Equity Interest
48.46
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-49.04
-70.00%
-28.85
+37.86%
-46.42
+11.52%
-52.47
Cash Flow From Continuing Operating Activities
-49.04
-70.00%
-28.85
+37.86%
-46.42
+11.52%
-52.47
Net Income From Continuing Operations
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Depreciation Amortization Depletion
0.11
+8.57%
0.10
+14.13%
0.09
+3.37%
0.09
Depreciation
0.11
+8.57%
0.10
+14.13%
0.09
+3.37%
0.09
Depreciation And Amortization
0.11
+8.57%
0.10
+14.13%
0.09
+3.37%
0.09
Other Non Cash Items
3.84
+7.23%
3.58
+40.17%
2.55
—
Stock Based Compensation
7.46
+29.17%
5.78
-39.42%
9.53
+5.37%
9.05
Operating Gains Losses
—
0.01
—
0.14
Gain Loss On Sale Of PPE
0.00
-100.00%
0.01
0.00
-100.00%
0.14
Change In Working Capital
2.68
-26.59%
3.66
+194.13%
1.24
+138.11%
-3.26
Change In Receivables
-1.12
-176.51%
1.46
+155.34%
-2.64
-261.37%
-0.73
Change In Inventory
-0.65
0.00
—
—
Change In Prepaid Assets
0.03
-97.83%
1.34
-52.67%
2.83
+265.71%
-1.71
Change In Payables And Accrued Expense
4.43
+406.51%
0.88
-15.54%
1.04
+214.22%
-0.91
Change In Other Working Capital
-0.01
+29.41%
-0.02
-194.44%
0.02
-77.78%
0.08
Investing Cash Flow
11.25
+35.77%
8.28
+74.16%
4.76
+108.33%
-57.12
Cash Flow From Continuing Investing Activities
11.25
+35.77%
8.28
+74.16%
4.76
+108.33%
-57.12
Net PPE Purchase And Sale
-0.30
-815.15%
-0.03
+70.54%
-0.11
+58.82%
-0.27
Purchase Of PPE
-0.30
-815.15%
-0.03
+70.54%
-0.11
+58.82%
-0.27
Capital Expenditure
-0.30
-815.15%
-0.03
+70.54%
-0.11
+58.82%
-0.27
Net Investment Purchase And Sale
11.55
+38.86%
8.32
+70.83%
4.87
+108.56%
-56.85
Purchase Of Investment
-82.92
+26.98%
-113.55
+17.19%
-137.13
-59.73%
-85.85
Sale Of Investment
94.47
-22.49%
121.87
-14.18%
142.00
+389.66%
29.00
Financing Cash Flow
85.53
+166.28%
32.12
-32.79%
47.79
+1447.67%
3.09
Cash Flow From Continuing Financing Activities
85.53
+166.28%
32.12
-32.79%
47.79
+1447.67%
3.09
Net Issuance Payments Of Debt
—
0.00
-100.00%
50.00
0.00
Issuance Of Debt
—
0.00
-100.00%
50.00
0.00
Long Term Debt Issuance
—
0.00
-100.00%
50.00
0.00
Net Long Term Debt Issuance
—
0.00
-100.00%
50.00
0.00
Net Common Stock Issuance
51.01
+87.13%
27.26
0.00
-100.00%
2.63
Proceeds From Stock Option Exercised
34.52
+610.10%
4.86
+746.86%
0.57
+25.33%
0.46
Net Other Financing Charges
—
—
-2.78
—
Changes In Cash
47.73
+313.12%
11.55
+88.67%
6.12
+105.75%
-106.50
Beginning Cash Position
25.31
+83.97%
13.76
+80.20%
7.64
-93.31%
114.14
End Cash Position
73.05
+188.56%
25.31
+83.97%
13.76
+80.20%
7.64
Free Cash Flow
-49.34
-70.85%
-28.88
+37.94%
-46.54
+11.77%
-52.74
Amortization Of Securities
-0.08
+82.16%
-0.45
-180.25%
-0.16
-67.01%
-0.10
Common Stock Issuance
51.01
+87.13%
27.26
0.00
-100.00%
2.63
Issuance Of Capital Stock
51.01
+87.13%
27.26
0.00
-100.00%
2.63
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category